Key Findings from the Research of Hossam Hamdy Elsayed Elnoumany, MBA – IBAS Switzerland

While many businesses throughout the world saw unprecedented upheaval in the aftermath of COVID-19, few were as severely affected as the pharmaceutical industry. This article examines how the pandemic affected pharmaceutical operations, with a particular emphasis on resource management issues, drawing on the perceptive research of Hossam Hamdy Elsayed Elnoumany, who presented it as a partial requirement for his MBA degree at the International Business Academy of Switzerland (IBAS).

In addition to identifying what management approaches failed, what worked, and what needs to change going ahead, the research focuses on how the pandemic affected the execution of activities and the allocation of resources. Using data from SPIMACO Pharmaceuticals, the results show both quantitative and qualitative evaluations obtained using the Delphi technique and statistical analysis.

The Pharmaceutical Industry Under Pandemic Stress

At the same time, the pharmaceutical industry was both at the forefront of the worldwide reaction to COVID-19 and the target of its most significant disruptions. The sector could not afford to cease as a supplier of vital services and goods, but operational processes, supply chains, and human resources all experienced significant losses.

The study reveals:

• There was a considerable correlation between pandemic intensity and activity execution.
• There were moderate to severe disruptions in resource management.
• There was a discernible increase in execution and resource issues as the pandemic’s intensity increased.

“Activity execution and resource management were statistically significant at the 1% level and had positive signs… if COVID-19 increases by one unit, the challenges increase by 0.52 and 0.49 units respectively.” – Hossam, 2024

Key Challenges in Resource Management

1. Human Resource Limitations

Workforce availability decreased due to quarantine regulations, social distancing policies, and health hazards. Reduced productivity in all divisions was caused by psychological stress, a lack of employees, and an increase in sick absence.

• Travel restrictions hindered inter-site collaboration.
• Health risks are limited to on-site operations.
• SOP adherence added delays and bottlenecks.

2. Material Shortages and Logistical Breakdowns

Widespread supply chain disruptions resulted from the closure of the industrial and transportation sectors.

• Obtaining components and raw materials became challenging.
• Delivery delays were caused by import-export restrictions.
• Unpredictable demand caused inventory planning to fail.

“The un-functionality of transport and manufacturing made the unavailability of materials a major bottleneck. Very few strategies were adopted to manage these issues.” – Hossam, 2024

Measuring the Impact: Activity Execution Breakdown

Pharmaceutical businesses must adhere to stringent manufacturing, testing, and delivery schedules. This cycle was upset by the epidemic.

1. Delayed Projects and Postponements

• Initiatives for research and development were put on hold or postponed.
• In such instances, routine manufacturing timetables doubled.
• Drug clearances and clinical testing were delayed.2. Low Adoption of New Technologies

The study highlights a surprising insight: digital transformation was minimal.

• Automation and cloud-based project tracking were not widely adopted by businesses.
• The use of digital technologies for monitoring and communication was underutilized.
• The industry lost time and flexibility as a result of its cautious approach.

“Very low progress was made in adopting new strategies. The use of technology to manage the pharmaceutical industry was minimal.” – Hossam, 2024

Organizational Response: Where Leadership Fell Short

While the crisis was unprecedented, the industry’s lack of preparedness worsened its effects.

Weaknesses Identified:

• Lack of contingency planning
• Minimal investment in risk forecasting
• Inadequate training in crisis resource management

Even though their profession is based on scientific accuracy and long-term planning, many managers were forced to respond to problems as they arose rather than proactively addressing them.

“Management faced unexpected and unpredictable challenges… with each unit increase in pandemic severity, resource challenges increased by 0.49.” – Hossam, 2024

The Human Cost: Beyond the Boardroom

The study also touches on the social implications that spilled over into the workforce:

• Burnout was caused by psychological and emotional stress.
• Morale problems were brought on by an increase in workload and safety concerns.
• Team cohesiveness was undermined by communication failures in distant work settings.

The pandemic blurred the line between professional operations and public health emergencies, putting pharmaceutical employees under immense pressure.

Recommendations: What Must Be Done

Hossam’s research offers clear and practical recommendations for preparing the pharmaceutical industry for future crises:

1. Build an Environmental Risk Factor Matrix

This tool would allow companies to:

• Evaluate vulnerabilities in supply chains and workforce availability.
• Create flexible operating frameworks that can adapt quickly to external shocks.
• Simulate crisis scenarios to test preparedness.

2. Adopt Digital and Automation Solutions

The industry must overcome its digital inertia.

• Cloud systems should be integrated for project tracking.
• Predict supply chain bottlenecks with AI.
• Use HR tools that are accessible from a distance to improve staff management.

3. Expand the Scope of Future Studies

The research is currently limited to one pharmaceutical company (SPIMACO). Broader studies should include:

• International businesses
• Effects on Occupational Safety and Health
• A comparison between emerging and mature markets

“Future research should explore the pandemic’s occupational health implications and widen its scope beyond one company.” – Hossam, 2024

Lessons from the Data: A Quantitative Snapshot

The research used a demographic-based Delphi method and statistical regression to ensure accuracy.

Key Findings:

• The majority of respondents (46%) had 1–5 years of experience.
• 37% were aged between 26–30 years.
• 45% held a bachelor’s degree.

This highlights that early-career professionals were most affected and that junior staff bore the brunt of operational and resource challenges.

Long-Term Industry Impact

The implications of the COVID-19 crisis are long-lasting:

• Supply chain redesigns are now a strategic priority.
• Remote workforce models must be formalized.
• Cross-training and employee versatility should be emphasized to build flexible teams.

“COVID-19 changed the way pharmaceutical companies work. Now, strategic preparedness is not optional—it’s mandatory.” – Hossam, 2024

Final Thoughts: Crisis as Catalyst

The COVID-19 pandemic revealed weaknesses in the pharmaceutical sector, but it also presented an opportunity. Businesses can emerge stronger if they heed the warnings, make resilience investments, and implement progressive management techniques.

A strong case for strategic renewal in pharmaceutical resource management can be found in Hossam Hamdy Elsayed Elnoumany’s research. It highlights that leadership’s capacity to strategize, change course, and endure will be more critical for survival in future global crises than scientific discoveries alone.

Conclusion: Managing Resources in a Post-Pandemic World

The COVID-19 pandemic exposed structural flaws in how the pharmaceutical industry manages its most critical asset: resources.  Elnoumany’s research highlights the operational weaknesses that must be addressed for the sector to remain viable in the face of future global threats.

Pharmaceutical companies must embrace innovation not just in the lab, but in their management systems. A resilient future demands it.

For professionals seeking to drive change and resilience in global industries, an MBA or DBA degree from IBAS can provide the strategic knowledge, leadership skills, and crisis management tools needed to navigate tomorrow’s challenges.

Join IBAS–VERN to leverage world-class education, expand your global perspective, and lead transformation in the modern business environment.